Latest & greatest articles for escitalopram

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on escitalopram or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on escitalopram and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for escitalopram

21. Escitalopram may improve some cognitive functions after stroke in non-depressed patients

Escitalopram may improve some cognitive functions after stroke in non-depressed patients Escitalopram may improve some cognitive functions after stroke in non-depressed patients | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Escitalopram may improve some cognitive functions after stroke in non-depressed patients Article Text Therapeutics Escitalopram may improve some cognitive functions after stroke in non-depressed patients Statistics from Altmetric.com No Altmetric data available for this article. Question Question: Does

Evidence-Based Mental Health2010

22. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial

Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial 19465881 2009 06 24 2009 10 05 2013 11 21 1527-5418 48 7 2009 Jul Journal of the American Academy of Child and Adolescent Psychiatry J Am Acad Child Adolesc Psychiatry Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. 721-9 10.1097/CHI.0b013e3181a2b304 This article presents the results from a prospective, randomized, double-blind, placebo (...) -controlled trial of escitalopram in adolescent patients with major depressive disorder. Male and female adolescents (aged 12-17 years) with DSM-IV-defined major depressive disorder were randomly assigned to 8 weeks of double-blind treatment with escitalopram 10 to 20 mg/day (n = 155) or placebo (n = 157). The primary efficacy parameter was change from baseline to week 8 in Children's Depression Rating Scale-Revised (CDRS-R) score using the last observation carried forward approach. A total of 83

EvidenceUpdates2009

23. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression

Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression 19252156 2009 03 02 2009 06 02 2016 11 22 1472-1465 194 3 2009 Mar The British journal of psychiatry : the journal of mental science Br J Psychiatry Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. 252-9 10.1192/bjp.bp.108.057554 Tricyclic antidepressants and serotonin reuptake inhibitors are considered to be equally effective, but differences may have been (...) obscured by internally inconsistent measurement scales and inefficient statistical analyses. To test the hypothesis that escitalopram and nortriptyline differ in their effects on observed mood, cognitive and neurovegetative symptoms of depression. In a multicentre part-randomised open-label design (the Genome Based Therapeutic Drugs for Depression (GENDEP) study) 811 adults with moderate to severe unipolar depression were allocated to flexible dosage escitalopram or nortriptyline for 12 weeks

EvidenceUpdates2009

24. Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder

Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder Xie F, Despiegel N, Danchenko N, Hansen K Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of escitalopram versus venlafaxine and versus fluvoxamine in first-line therapy for patients with major depressive disorder. The authors concluded that escitalopram was a cost-effective option in their setting, when compared

NHS Economic Evaluation Database.2009

25. Escitalopram modestly improves generalised anxiety disorder in older adults in treatment completers

Escitalopram modestly improves generalised anxiety disorder in older adults in treatment completers Escitalopram modestly improves generalised anxiety disorder in older adults in treatment completers | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Escitalopram modestly improves generalised anxiety disorder in older adults in treatment completers Article Text Therapeutics Escitalopram modestly improves generalised anxiety disorder in older adults in treatment completers Statistics from Altmetric.com No Altmetric data available for this article

Evidence-Based Mental Health2009

26. Escitalopram in the treatment of major depressive disorder: a meta-analysis

Escitalopram in the treatment of major depressive disorder: a meta-analysis Escitalopram in the treatment of major depressive disorder: a meta-analysis Escitalopram in the treatment of major depressive disorder: a meta-analysis Kennedy SH, Andersen HF, Thase ME CRD summary This individual patient data review concluded that escitalopram was superior to other selected antidepressants for the treatment of major depressive disorder, largely explained by differences between escitalopram (...) and citalopram. There were several potential methodological limitations in the review, including the search strategy, validity assessment, reporting of results, and the general review process. The reliability of the authors' conclusions is unclear. Authors' objectives To compare the efficacy of escitalopram and comparator antidepressants in the treatment of major depressive disorder. Searching MEDLINE, EMBASE and the Cochrane Library were searched from 1966 to 2007. Search terms were reported. Reference

DARE.2009

27. Escitalopram and problem solving therapy reduce the incidence of post-stroke depression

Escitalopram and problem solving therapy reduce the incidence of post-stroke depression Escitalopram and problem solving therapy reduce the incidence of post-stroke depression | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Escitalopram and problem solving therapy reduce the incidence of post-stroke depression Article Text Therapeutics Escitalopram and problem solving therapy reduce the incidence of post-stroke depression Statistics from Altmetric.com No Altmetric data available for this article. QUESTION Question: Can escitalopram or problem

Evidence-Based Mental Health2009

28. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial.

Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. 19155456 2009 01 21 2009 01 23 2016 12 15 1538-3598 301 3 2009 Jan 21 JAMA JAMA Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. 295-303 10.1001/jama.2008.977 Generalized anxiety disorder (GAD) is one of the most common psychiatric disorders in older adults; however, few data exist to guide clinicians in efficacious and safe treatment (...) . Selective serotonin reuptake inhibitors (SSRIs) are efficacious for younger adults with GAD, but benefits and risks may be different in older adults. To examine the efficacy, safety, and tolerability of the SSRI escitalopram in older adults with GAD. A randomized controlled trial in primary care practices and related specialty clinics in Pittsburgh, Pennsylvania, of 177 participants aged 60 years or older with a principal diagnosis of GAD randomized to receive either escitalopram or placebo and conducted between January 2005

JAMA2009 Full Text: Link to full Text with Trip Pro

29. Escitalopram 10 mg daily is more effective than paroxetine and placebo for generalised anxiety disorder

Escitalopram 10 mg daily is more effective than paroxetine and placebo for generalised anxiety disorder Escitalopram 10 mg daily is more effective than paroxetine and placebo for generalised anxiety disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Escitalopram 10 mg daily is more effective than paroxetine and placebo for generalised anxiety disorder Article Text Therapeutics Escitalopram 10 mg daily is more effective than paroxetine and placebo for generalised anxiety disorder Statistics from Altmetric.com No Altmetric data available

Evidence-Based Mental Health2008

30. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder

Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder 18344730 2008 03 17 2008 05 27 2013 11 21 0271-0749 28 2 2008 Apr Journal of clinical psychopharmacology J Clin Psychopharmacol Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. 195-202 10.1097/JCP.0b013e3181678a28 This is the first placebo-controlled trial evaluating the efficacy (...) of the selective serotonin reuptake inhibitor (SSRI), escitalopram, in the treatment of premenstrual dysphoric disorder (PMDD). Women with PMDD (intention-to-treat population, n = 151) were treated intermittently for 3 months, during luteal phases only, with 10 mg/d escitalopram, 20 mg/d escitalopram, or placebo. Escitalopram was found to exert a marked and a dose-dependent symptom-reducing effect, 20 mg/d being clearly superior to 10 mg/d. Although the primary outcome parameter, that is, the sum of the symptoms irritability, depressed

EvidenceUpdates2008

31. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder

A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder Armstrong EP, Malone DC, Erder MH Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to compare the cost-effectiveness of two branded treatments for major depressive disorder. The authors concluded that escitalopram was more effective and less costly than duloxetine. The methodology appears to have been appropriate and, on the whole, was clearly and transparently reported. The conclusions

NHS Economic Evaluation Database.2008

32. The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation

The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation Kongsakon R, Bunchapattanasakda C Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of escitalopram versus fluoxetine and venlafaxine for the treatment of major depressive disorder. The authors concluded that escitalopram was more

NHS Economic Evaluation Database.2008

33. Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada

Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada Iskedjian M, Walker JH, Bereza BG, Le Melledo JM, Einarson TR Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess the cost-effectiveness of escitalopram compared with paroxetine for generalised anxiety disorder. The authors concluded that escitalopram was more cost-effective than paroxetine, indicating an advantage over paroxetine. Overall, the methodology was satisfactory and the results were well reported. The authors' conclusions appear to be robust and appropriate. Type

NHS Economic Evaluation Database.2008

34. Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder

Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention (...) of escitalopram in comparison with no treatment for patients with generalised social anxiety disorder. The authors concluded that escitalopram improved health-related quality of life without significantly increasing the cost of care. The additional drug costs were offset by savings in physician visits and in-patient care. Overall, the clinical and economic analyses were carried out transparently and credibly. The authors’ conclusions appear to be valid. Type of economic evaluation Cost-effectiveness analysis

NHS Economic Evaluation Database.2008

35. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data

Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data Wade A G, Fernandez J L, Francois C, Hansen K, Danchenko N, Despiegel N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of escitalopram and duloxetine in the treatment of major depressive disorder (MDD) in the UK. The authors concluded that, from a UK societal perspective, escitalopram led to a reduction in costs and improved clinical outcomes in comparison

NHS Economic Evaluation Database.2008

37. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial.

Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. 18505948 2008 05 28 2008 06 03 2016 12 28 1538-3598 299 20 2008 May 28 JAMA JAMA Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. 2391-400 10.1001/jama.299.20.2391 Depression occurs in more than half of patients who have experienced a stroke. Poststroke depression has been shown in numerous studies to be associated (...) with both impaired recovery in activities of daily living and increased mortality. Prevention of depression thus represents a potentially important goal. To determine whether treatment with escitalopram or problem-solving therapy over the first year following acute stroke will decrease the number of depression cases that develop compared with placebo medication. A multisite randomized controlled trial for prevention of depression among 176 nondepressed patients was conducted within 3 months following

JAMA2008 Full Text: Link to full Text with Trip Pro

39. Continued escitalopram reduces risk of relapse in people with generalised social anxiety disorder

Continued escitalopram reduces risk of relapse in people with generalised social anxiety disorder Continued escitalopram reduces risk of relapse in people with generalised social anxiety disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Continued escitalopram reduces risk of relapse in people with generalised social anxiety disorder Article Text Therapeutics Continued escitalopram reduces risk of relapse in people with generalised social anxiety disorder Statistics from Altmetric.com No Altmetric data available for this article. Montgomery

Evidence-Based Mental Health2007

40. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.

Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Major depressive disorder (MDD), a prevalent and serious mental illness, is associated with a substantial disease and economic burden. Long-term pharmacotherapy is often necessary; selective serotonin reuptake inhibitors (SSRIs) or the serotonin-noradrenaline reuptake inhibitor venlafaxine are the most frequently prescribed medications (...) in patients with moderate-to-severe depressive symptoms. This article reviews head-to-head clinical studies and health economic models comparing the efficacy, tolerability and cost-effectiveness of escitalopram, a dual-action selective inhibitor of serotonin reuptake, and the extended-release (XR) formulation of venlafaxine. While there has been some evidence that conventional SSRIs are inferior to venlafaxine in terms of efficacy, escitalopram was at least as effective as venlafaxine XR in reducing

EvidenceUpdates2007